Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma.
Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, Sangro B, Sharma R, Verslype C, Basu B, Sengel C, Ricke J, Schebb NH, Weylandt KH, Benckert J. Leineweber CG, et al. Among authors: benckert j. Front Pharmacol. 2023 Mar 3;14:1124214. doi: 10.3389/fphar.2023.1124214. eCollection 2023. Front Pharmacol. 2023. PMID: 36937889 Free PMC article.
Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study.
Cornberg M, Pischke S, Müller T, Behrendt P, Piecha F, Benckert J, Todt D, Steinmann E, Papkalla A, von Karpowitz M, Koch A, Lohse A, Hardtke S, Manns MP, Wedemeyer H. Cornberg M, et al. Among authors: benckert j. J Hepatol. 2020 Sep;73(3):696-699. doi: 10.1016/j.jhep.2020.05.020. Epub 2020 Jul 2. J Hepatol. 2020. PMID: 32624195 Clinical Trial. No abstract available.
Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
Alunni-Fabbroni M, Rönsch K, Huber T, Cyran CC, Seidensticker M, Mayerle J, Pech M, Basu B, Verslype C, Benckert J, Malfertheiner P, Ricke J. Alunni-Fabbroni M, et al. Among authors: benckert j. J Transl Med. 2019 Oct 1;17(1):328. doi: 10.1186/s12967-019-2079-9. J Transl Med. 2019. PMID: 31570105 Free PMC article. Clinical Trial.
Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
Öcal O, Schütte K, Kupčinskas J, Morkunas E, Jurkeviciute G, de Toni EN, Ben Khaled N, Berg T, Malfertheiner P, Klümpen HJ, Sengel C, Basu B, Valle JW, Benckert J, Gasbarrini A, Palmer D, Seidensticker R, Wildgruber M, Sangro B, Pech M, Ricke J, Seidensticker M. Öcal O, et al. Among authors: benckert j. J Cancer Res Clin Oncol. 2022 Feb;148(2):475-485. doi: 10.1007/s00432-021-03627-1. Epub 2021 Apr 14. J Cancer Res Clin Oncol. 2022. PMID: 33855585 Free PMC article. Clinical Trial.
Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization.
Öcal O, Kupčinskas J, Morkunas E, Amthauer H, Schütte K, Malfertheiner P, Klümpen HJ, Sengel C, Benckert J, Seidensticker R, Sangro B, Wildgruber M, Pech M, Bartenstein P, Ricke J, Seidensticker M. Öcal O, et al. Among authors: benckert j. EJNMMI Res. 2021 Jun 2;11(1):51. doi: 10.1186/s13550-021-00791-w. EJNMMI Res. 2021. PMID: 34080071 Free PMC article.
Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial.
Shuen TWH, Alunni-Fabbroni M, Öcal E, Malfertheiner P, Wildgruber M, Schinner R, Pech M, Benckert J, Sangro B, Kuhl C, Gasbarrini A, Chow PKH, Toh HC, Ricke J. Shuen TWH, et al. Among authors: benckert j. Clin Cancer Res. 2022 Sep 1;28(17):3890-3901. doi: 10.1158/1078-0432.CCR-22-0569. Clin Cancer Res. 2022. PMID: 35763041 Free PMC article. Clinical Trial.
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib.
Öcal O, Schütte K, Zech CJ, Loewe C, van Delden O, Vandecaveye V, Verslype C, Gebauer B, Sengel C, Bargellini I, Iezzi R, Philipp A, Berg T, Klümpen HJ, Benckert J, Pech M, Gasbarrini A, Amthauer H, Bartenstein P, Sangro B, Malfertheiner P, Ricke J, Seidensticker M. Öcal O, et al. Among authors: benckert j. Eur J Nucl Med Mol Imaging. 2022 Nov;49(13):4716-4726. doi: 10.1007/s00259-022-05920-8. Epub 2022 Aug 2. Eur J Nucl Med Mol Imaging. 2022. PMID: 35916920 Free PMC article.
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial.
Surov A, Thormann M, Hinnerichs M, Seidensticker M, Seidensticker R, Öcal O, Schütte K, Zech CJ, Loewe C, van Delden O, Vandecaveye V, Verslype C, Gebauer B, Sengel C, Bargellini I, Iezzi R, Berg T, Klümpen HJ, Benckert J, Gasbarrini A, Amthauer H, Sangro B, Malfertheiner P, Omari J, Wienke A, Ricke J, Pech M. Surov A, et al. Among authors: benckert j. Hepatol Commun. 2023 May 23;7(6):e0165. doi: 10.1097/HC9.0000000000000165. eCollection 2023 Jun 1. Hepatol Commun. 2023. PMID: 37219875 Free PMC article. Clinical Trial.
Prognostic role of radiomics-based body composition analysis for the 1-year survival for hepatocellular carcinoma patients.
Saalfeld S, Kreher R, Hille G, Niemann U, Hinnerichs M, Öcal O, Schütte K, Zech CJ, Loewe C, van Delden O, Vandecaveye V, Verslype C, Gebauer B, Sengel C, Bargellini I, Iezzi R, Berg T, Klümpen HJ, Benckert J, Gasbarrini A, Amthauer H, Sangro B, Malfertheiner P, Preim B, Ricke J, Seidensticker M, Pech M, Surov A. Saalfeld S, et al. Among authors: benckert j. J Cachexia Sarcopenia Muscle. 2023 Oct;14(5):2301-2309. doi: 10.1002/jcsm.13315. Epub 2023 Aug 17. J Cachexia Sarcopenia Muscle. 2023. PMID: 37592827 Free PMC article.
18 results